Medical trial of firm’s osteoporosis drug is at the moment underway in postmenopausal ladies at excessive danger of fractures.
Medical stage biotech Angitia Biopharmaceuticals, a clinical-stage biotechnology firm has introduced the profitable closing of a $120 million Sequence C financing spherical. The capital raised will probably be used to advance the corporate’s pipeline of therapeutics focusing on critical musculoskeletal ailments, together with osteoporosis.
Headquartered in Woodland Hills, California, Angitia’s pipeline contains three lead candidates at the moment in scientific growth: AGA2118 for osteoporosis, AGA2115 for osteogenesis imperfecta, and AGA111 for spinal fusion. Osteoporosis, a widespread systemic skeletal illness characterised by lowered bone mass and structural deterioration affecting greater than 200 million people worldwide. The situation is a rising well being concern amongst growing old populations, significantly affecting ladies of menopausal age and older.
AGA2118 is a bispecific antibody focusing on the proteins sclerostin and DKK1, that are unfavorable regulators of WNT signaling, essential for osteoblast operate and bone metabolism. By concurrently inhibiting these proteins, AGA2118 goals to counteract compensatory will increase in both molecule, probably resulting in higher bone mineral density enhancements.
At present, AGA2118 is present process scientific analysis within the ARTEMIS Part 2 research, which focuses on long-term outcomes in postmenopausal ladies at excessive danger of fractures. Final month, Angitia introduced the dosing of the first patient in ARTEMIS, which goals to incorporate roughly 350 members, with a main endpoint of BMD modifications on the lumbar backbone after 12 months.
The most recent funding spherical was led by Bain Capital Life Sciences, with participation from new and present traders, together with Janus Henderson, OrbiMed, 3H Well being Funding, Yonghua Capital, Legend Capital and Elikon Enterprise. Along with the financing announcement, Angitia additionally introduced the appointment of Dr Norbert Riedel to its Board of Administrators. The business veteran beforehand held roles at Aptinyx, Naurex, Baxter Worldwide and Sanofi.
